Posted in Immunotherapy

Physicians at City of Hope, working in collaboration with scientists at Translational Genomics Research Institute (TGen), have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on Food and Drug Administration-approved immunotherapy regimens. Their findings are outlined in a study published in the journal European Urology.
“We also reported the changes over time in the gut microbiome that occur during the c...

T cells are the immune system's SWAT team. Their job is to constantly patrol the blood, lymphatic system, tissues, and organs. If they come across cells that are contaminated with or damaged by pathogens, they eliminate them. They can also recognise and destroy cancer cells. The problem, though, is that the tumour cells find ways of escaping this line of defence. Researchers around the world are working to prevent these evasive manoeuvres and harness T cells for targeted immunotherapies a...

Colon cancer is one of the most common types of cancer. Particularly in advanced stages of disease, the treatment still largely relies on traditional chemotherapy. The new generation of cancer treatments, so-called immunotherapies, has only been effective in a small subgroup of colon cancers. TU Dresden scientists led by Prof. Sebastian Zeissig have now identified proteins that are promising targets for new immunotherapies against colon cancer. Their results also underline the central role of...

Cancer patients who have run out of options for immunotherapy may have a new possibility. It’s the gut microbiome. By changing the gut microbiome in advanced melanoma patients, who had previously failed to respond to treatment, the body responded to anti-PD-1 immunotherapy. Though the research is in phase II trials, it’s very positive news for those who have little hope. Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrated that changing t...

Recent research has shown that immunotherapy given before surgery caused liver cancer tumours to die off in one-third of the patients enrolled in a first-of-its-kind clinical trial. Mount Sinai researchers reported their findings in The Lancet Gastroenterology & Hepatology - January 2022 The phase 2 trial results suggested that the neo-adjuvant immunotherapy -- therapy given before surgery -- may kill not only the tumour, but also microscopic cancer cells that surgery would miss and tha...